Papyrus Australia Limited (PPY) News

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form POS AM - Post-Effective amendments for registration statement

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Form 8-K - Current report

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to...

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a...

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a...